The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention

Journal of Invasive Cardiology

Volumn 22, Issue 1, 2010, Pages 2-6

  Saltzman, Adam J ^a   Mehran, Roxana ^a   Hooper, W Craig ^a,b   Moses, Jeffrey W ^a   Weisz, Giora ^a   Collins, Michael B ^a   Lansky, Alexandra J ^a   Kreps, Edward M ^a   Leon, Martin B ^a   Stone, Gregg W ^a   Dangas, George ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Glycoprotein IIb IIIa receptor antagonists; Inflammation; Percutaneous coronary intervention; Platelet inhibition

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; CORRELATION COEFFICIENT; DEATH; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STENT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASCULAR DISEASE;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS; TIME FACTORS; TYROSINE;

EID: 76849083584     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dangas G, Colombo A. The role of platelet glycoprotein GP IIb/IIIa inhibitors in coronary interventional procedures. Am Heart J, in press.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
3. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-2380.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
5. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patient undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
6. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689.
7. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
8. Topol EJ, Ferguson JJ, Weisman HF, et. al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.
9. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
10. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.
11. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
12. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-1423.
13. Batchelor WB, Tolleson TR, Huang, Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: The COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002;106:1470-1476.
14. Topol EJ, Moliterno DJ, Hermann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
15. (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
16. (REVERSAL) Investigators. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med 2005;352:29-38.
17. Ridker PM, Hennekens CH, Buring JE, et al. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
18. Furman MI, Krueger LA, Linden MD, et al. GP IIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005;3:312-320.
19. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-1128.
20. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thrombosis Research 2002;107:121-128.
21. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.